BALAXI PHARMACEUTICALS LIMITED — PPTs, 06-08-2026: Investor Presentation

Balaxi Pharma delivered a strong Q1 FY27 performance, with consolidated revenue up 14% YoY to ₹80.68 Cr. Profit after tax (PAT) surged 347% to ₹1.29 Cr, while gross profit margin expanded by 241 basis points to 46.5%. Africa and LATAM contributed 54% and 46% respectively to revenue, with generics making up 60% of products.

The company's strategy focuses on institutional business expansion, portfolio diversification, and backward integration. A significant milestone was achieved with commercial production commencing at its first pharma formulation facility in Jadcherla, Hyderabad, now approved for 31 products. Balaxi also secured 16 new product registrations, bringing its total to 980.

Q1 FY27 EPS rose to ₹0.24 from ₹0.05 YoY (+380%). Management anticipates further profitability gains as operating leverage strengthens and plans to expand its institutional business, strengthen market presence in Africa and Latin America, and accelerate manufacturing facility utilization. The strategic exit from the Ancillary Building Hardware business aims to improve working capital.